Selecting adjuvant endocrine therapy for breast cancer

ONCOLOGY

Volumn 18, Issue 14, 2004, Pages 1733-1743

  Eneman, Jonathan D ^a,b   Wood, Marie E ^a   Muss, Hyman B ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST TUMOR; CASE REPORT; DOSE RESPONSE; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; METABOLISM; MIDDLE AGED; NEOPLASM; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEVERITY OF ILLNESS INDEX; TAMOXIFEN; TREATMENT OUTCOME;

EID: 16244411106     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54:8-29, 2004.
2. Peto R, Boreham J, Clarke M, et al: UK and USA breast cancer deaths down 25 percent at ages 20-69 years. Lancet 355:1822, 2000.
3. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351:1451-1467, 1998.
4. de Haes H, Olschewski M, Kaufmann M: Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node positive, early breast cancer: The Zoladex Early Breast Cancer Research Association Trialists Group. J Clin Oncol 21:4510-4516, 2003.
5. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 2:104-107, 1896.
6. Haddow A, Watkinson JM, Patterson E, et al: Influence of synthetic estrogens upon advanced malignant disease. Br Med J 2:393-398, 1944.
7. Huggins C, Bergenstal DM: Inhibition of human mammary and prostatic cancer by adrenalectomy. Cancer Res 12:134-141, 1952.
8. Robin PE, Powell DJ, Waterhouse JA, et al: Transphenoidal hypophysectomy in disseminated carcinoma of the breast. Br J Surg 62:85-91, 1975.
9. Tormey DC, Gray R, Falkson HC: Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst 88:1828-1833, 1996.
10. Fisher B, Dignam J, Bryant J, et al: Five vs more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684-690, 2001.
11. Stewart HJ, Forrest APM, Everington D, et al: Randomized comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. Br J Cancer 74:297-299, 1996.
12. Kass R, Peterse JL, Hart AAM, et al: The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer. Br J Cancer 88:707-710, 2003.
13. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2001:CD000486.
14. Fisher B, Anderson S, Tan-Chiu E, et al: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor negative breast cancer. Findings from National Breast and Bowel Project B-23, J Clin Oncol 19:931-942, 2001.
15. Swain SM: Tamoxifen for patients with estrogen receptor negative breast cancer. J Clin Oncol 19:93s-97s, 2001.
16. Hutchins L, Green S, Ravdin P, et al: CMF versus CAF+/- tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: Update of tamoxifen results (abstract). Breast Can Res Treat 57:25, 1999.
17. Powles TJ, Hickish TF, Kanis JA, et al: Tamoxifen preserves bone mineral density in premenopausal women (abstract). Proc Am Soc Clin Oncol 14:165, 1995.
18. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project p-1 study. J Natl Cancer Inst 90:1371-1388, 1998.
19. Cushman M, Constantino JP, Bovill EG, et al: Effect of tamoxifen on venous thrombosis risk factors in women without cancer: The breast cancer prevention trial. Br J Hematol 120:109-116, 2003.
20. Goodwin PJ, Ennis M, Pritchard KI, et al: Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17:2365-2370, 1999.
21. Bernstein L, Deapen D, Cerhan JR, et al: Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 91:1654-1662, 1999.
22. Saga Y, Ohwada M, Kohno T, et al: High grade endometrial stromal sarcoma after treatment with tamoxifen in a patient treated for breast cancer. Int J Gynecol Cancer 13:690-692, 2003.
23. Kaiser-Kupfer MI, Lippman ME: Tamoxifen retinopathy. Cancer Treat Rep 62:315-320, 1978.
24. Early Breast Cancer Trialists' Collaborative Group: Ovarian ablation in early breast cancer: overview of randomized trials. Lancet 348:1189-1196, 1996.
25. Early Breast Cancer Trialists' Collaborative Group: Ovarian ablation for early breast cancer. Cochrane Database Syst Rev 2000:CD000485.
26. Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615, 2002.
27. Rebbeck TR, Lynch HT, Neuhausen SL, et al: The prevention and observation of surgical end points study group: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622, 2002.
28. Paoletti AM, Serra GG, Cagnacci A, et al: Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Fertil Steril 65:707-710, 1996.
29. Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718-1729, 1996.
30. Stone ER, Slack RS, Novielli A, et al: Rate of chemotherapy related amenorrhea (CRA) associated with adjuvant Adriamycin and Cytoxan followed by Taxol (AC+T) in early stage breast cancer (abstract). Breast Cancer Res Treat 64:61, 2000.
31. Del Mastro L, Venturini M, Sertoli MR, et al: Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: Prognostic role and clinical applications. Breast Cancer Res Treat 43:183-190, 1997.
32. Pagani O, O'Neill A, Castiglione M, et al: Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34:632-640, 1998.
33. Levine MN, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer, National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651-2658, 1998.
34. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003.
35. Jonat W, Kaufmann M, Sauerbrei W, et al: Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20:4628-4635, 2002.
36. Jakesz R, Hausaninger H, Kubista E: Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20:4621-4627, 2002.
37. International Breast Cancer Study Group (IBCSG): Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node negative breast cancer: A randomized trial. J Natl Cancer Inst 95:1833-1846, 2003.
38. Fox KR, Scialla J, More H: Preventing chemotherapy-related amenorrhea using leuprolide during adjuvant chemotherapy for early-stage breast cancer (abstract 50). Proc Am Soc Clin Oncol 22:13, 2003.
39. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2127, 2002.
40. The ATAC Trialists Group: The ATAC trial in post-menopausal women with early breast cancer - updated efficacy results based on a median follow-up of 47 months (abstract). Breast Cancer Res Treat 82, 2003.
41. Baum M, Buzdar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen vs tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial. Efficacy and safety update analysis. Cancer 98:1802-1810, 2003.
42. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001.
43. Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in post-menopausal women: Results of a North American multicenter randomized trial. J Clin Oncol 18:3758-3767, 2000.
44. Bonneterre J, Thurlimann B, Robertson JFR, et al: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol 18:3748-3757, 2000.
45. Eirmann W, Paepke S, Appfelstaedt J, et al: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12:1527-1532, 2001.
46. Dixon JM, Anderson TJ, Miller WR: Neoadjuvant endocrine therapy of breast cancer: A surgical perspective. Eur J Cancer 38:2214-2221, 2002.
47. Buzdar AU, Valero V, Theriault RL, et al: Pathologic complete response to chemotherapy is related to hormone receptor status. Breast Cancer Res Treat 82:S69, 2003.
48. Boccardo F, Rubagotti A, Amoroso D, et al: Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian cooperative study. J Clin Oncol 19:4209-4215, 2001.
49. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003.
50. Boccardo F, Rubagotti A, Amoroso D, et al: Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 82:S6-S7, 2003.
51. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. 350:1081-1092, 2004.
52. Goss PE, Ingle JN, Martino S, et al: Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer, J Clin Oncol (2004 ASCO Annual Meeting Proceedings, Post-Meeting Edition) 22:847, 2004.
53. Harvey JM, Clark GM, Osborne K, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999.
54. Esteva FJ, Hortobagyi GN: Breast cancer management: Adjuvant systemic therapy for primary breast cancer. Surg Clin North Am 79:1075-1090, 1999.
55. Singletary SE, Allred C, Ashley P, et al: Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. J Clin Oncol 20:3628-3636, 2002.
56. Woo CS, Silberman H, Nakamura SK, et al: Lymph node status combined with lymphovascular invasion creates a more powerful tool for predicting outcome in patients with invasive breast cancer. Am J Surg 184:337-340, 2002.
57. The NCCN: Breast cancer clinical practice guidelines in oncology. JNCCN 1:148-188, 2003.
58. Aapro MS: Adjuvant therapy of primary breast cancer: A review of key findings from the 7th international conference, St Gallen, February 2001. Oncologist 6:376-385, 2001.
59. Lundin J, Lundin M, Holli K, et al: Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: Results from a nationwide study. J Clin Oncol 19:28-36, 2001.
60. Rosen PP, Groshen S, Saigo PE: Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: A study of 644 patients with median follow-up of 18 years. J Clin Oncol 7:1239-1251, 1989.
61. Adami HO, Malker B, Holmbert L, et al: The relation between survival and age at diagnosis in breast cancer. N Engl J Med 315:559-563, 1996.
62. Bernstein JL, Lapinski R, Lynch C, et al: Factors influencing mortality among young women with second primary breast carcinoma. Cancer 95:2051-2058, 2002.
63. Yuneik R, Ries LG, Yates JW: Breast cancer in aging women: A population-based study of contrasts in stage, surgery, and survival. Cancer 63:976-981, 1989.
64. Andrulis IL, Bull SB, Blackstein ME, et al: neu/erbB-2 amplification identifies a poor prognosis group of women with node negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16:1340-1349, 1998.
65. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2-postive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001.
66. Loprinzi CL, Ravdin RM: Decision making for patients with resectable breast cancer: Individualized decisions for and by patients and their physicians. JNCCN 1:189-196, 2003.
67. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decision about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991, 2001.
68. Adjuvant! Available online at www.adjuvantonline.com. Accessed November 2, 2004.
69. Loprinzi CL, Thomé SD: Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 19:3795-3797, 2001.
70. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumors. Nature 406:747-752, 2000.
71. Hedenfalk I, Duggan D, Chen Y, et al: Gene-expression profiles in hereditary breast cancer. N Engl J Med 344:539-548, 2001.
72. Paik S, Shak S, Tang G, et al: Multigene RT-PCR assay for prediction recurrence in node negative breast cancer patients - NSABP studies B-20 and B-14 (abstract). Breast Cancer Res Treat 82:16, 2003.
73. Esteva FJ, Sahin AA, Coombes K, et al: Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients - M. D. Anderson Clinical Validation Study (abstract 17). Breast Cancer Res Treat 82:S11, 2003.
74. Senn HJ, Thurlimann B, Goldhirsch A, et al: Comments of the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer. The Breast 12:569-582, 2003.
75. NSABP: The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: Preliminary results from NSABP Protocol B-27 (abstract). Breast Cancer Res Treat 69:210, 2001.
76. Dixon JM, Renshaw L, Bellamy C: The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: A randomized, double blind, single center study. Clin Cancer Res 6:2229-2235, 2000.
77. Walter LC, Covinsky KE: Cancer screening in elderly patients: A framework for individualized decision making. JAMA 285:2750-2756, 2001.